Northwire Canada EditionSunday, October 18, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Production / Operations

Bright Minds launches Prader-Willi program

DRUG · Price

Executive Summary

  • Bright Minds Biosciences has initiated a new Prader-Willi Syndrome (PWS) program, nominating BMB-105 as a new clinical candidate and launching the NOVA Phase 2a study for BMB-101 in PWS.
  • The company provided an operational update on BMB-101 for absence seizures (AS) and developmental and epileptic encephalopathies (DDE), noting no safety signals and confirming top-line data release in January 2026.
  • A Key Opinion Leader (KOL) event is scheduled for November 6, 2025, to discuss the PWS program, unmet medical needs, and the status of the ongoing epilepsy studies.

Key Details

  • PWS Program Initiation:
    • Nominated BMB-105 as a new clinical candidate for the PWS program.
    • Commencing Phase 2a (NOVA) study for BMB-101 to assess efficacy, safety, and tolerability in PWS patients.
    • Commencing a randomized Phase 1 placebo-controlled study for BMB-105 in healthy volunteers to evaluate safety, tolerability, pharmacokinetics, and food effect.
    • Strategic approach: After the BMB-101 proof-of-pharmacology study, the company plans to select and advance BMB-105 as the dedicated compound for PWS, aiming to reduce time to market by approximately one year.
  • BMB-101 Operational Update (Absence Seizures/DDE):
    • BMB-101 has been well tolerated with no drug-related serious adverse events or safety signals requiring protocol adjustments.
    • Exposure levels and tolerability are consistent with Phase 1 expectations, supporting future dose selection.
    • Open-label extension participation is proceeding well, with nearly all eligible patients electing to remain on therapy.
    • Top-line data for the current study will be released in early January 2026.
    • Planning for Phase 2/3 studies in DDE and Phase 2/3 in 2026.
  • NOVA Clinical Study Design (BMB-101 for PWS):
    • Double-blind, randomized, Phase 2a study lasting up to 16 weeks.
    • Four-week screening period to establish hyperphagia and behavioral symptoms.
    • Randomization 1:1 to BMB-101 or placebo.
    • Four-week weekly ascending maximum tolerated dose (MTD) titration phase followed by an eight-week maintenance phase.
    • Five clinic visits and four telephone visits.
    • Optional unblinded, open-label phase for up to nine months (extendable) for participants who complete the maintenance phase.
    • Primary Endpoint: Change from baseline in hyperphagia questionnaire for clinical trials (HQ-CT) scores.
    • Secondary Endpoints: Change from baseline in hyperphagia severity (Caregiver and Clinician Global Impression of Severity), global impression of severity/improvement, and PWS-associated behavioral issues.
  • KOL Event Details:
    • Date: November 6, 2025, at 10 a.m. ET.
    • Format: Virtual webcast with replay available.
    • Speakers include Dr. Jennifer Miller (University of Florida), Theresa V. Strong, PhD (Foundation for Prader Willi Research), and Elizabeth Roof, HSP, MA (Vanderbilt University).
    • Topics: Overview of PWS, unmet medical need, quality-of-life challenges, clinical assessment tools, and therapeutic rationale for 5-HT2C agonists.

Notable Quotes

  • "The initiation of our PWS program and NOVA clinical study are exciting next steps as we continue our development efforts to serve patients with rare diseases... 5-HT2C agonism offers a novel mechanism for PWS by targeting the underlying aspects of the disease." — Ian McDonald, CEO and Co-Founder.
  • "We believe it will pave the way forward for a pivotal study with BMB-105, our dedicated compound and expedite the development of the drug that aims at directly targeting the pathophysiology of PWS." — Ian McDonald.
Read the original news release →

More from Bright Minds Biosciences Inc